TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Concordance Between Ultra-low Dose (ULD) and Standard Dose CT Scans in the Search for Traumatic Brain Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients in an emergency situation with a head trauma requiring a scan, i.e. moderate or severe skull trauma, Group 1 or 2 according to the Brain Trauma Task Force classification (Guidelines for management of severe head injury. J Neurotrauma 2000 ; 17 : 507-11) as described by P. Schoettker et al. 2001).~* Patient with an isolated skull trauma or polytraumatized patient including skull trauma.~* Patient capable of giving informed consent or for whom a person of confidence or legal representative / family member has given informed consent and signed the consent form on the patient's behalf if the patient has been included in an emergency.~* Patients affiliated to or beneficiary of a health insurance scheme.~* All adult patients aged 18 or over.~Exclusion Criteria:~* Patients already taking part in another study for which it is not allowed to participate in other clinical studies.~* Patients in an exclusion period determined by another study.~* Patients who are pregnant, breastfeeding or about to give birth.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients requiring a CT scan in the search for cranial lesions following head trauma (Type: EXPERIMENTAL): All patients will undergo both conventional dose AND ultra low-dose CT scans in the search for cranial lesions following head trauma.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must be a participant from Study 104RA203 (NCT 00458861)~Exclusion Criteria:~* Participants with a significant change in medical history from their previous BG9924 Study 104RA203 (NCT 00458861).~* Nursing mothers, pregnant women, or women who are planning to become pregnant while in the study.~* Male and female participants of child-bearing potential not willing to practice effective birth control for the duration of the study.~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BG9924 (Type: EXPERIMENTAL): dosage administered as per Biogen-idec protocol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Bone marrow examination or peripheral blood analysis confirming active acute myeloid leukemia by WHO criteria~  * No M3 acute myeloid leukemia~* Not a candidate for allogenic bone marrow transplantation~* Patient must be in first relapse after having received induction chemotherapy~  * Received 1 or 2 courses with remission lasting at least 1 month~* Patients with chloromas or leukemia cutis are eligible~* No evidence of leptomeningeal involvement~PATIENT CHARACTERISTICS:~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2~* Liver enzymes (total bilirubin, aspartate aminotransferase (AST) and ALT) ≤ 2.5 times the upper limits of normal~  * Liver enzymes ≥ 2.5 are acceptable if physician documents that it is secondary to the disease~* Serum creatinine ≤ 3 mg/dL~* No poorly controlled medical conditions that would seriously complicate compliance with this study~* No other active primary malignancy other than carcinoma in situ of the cervix or basal cell carcinoma of the skin~* No New York Heart Association grade III or IV cardiac problems, defined as congestive heart failure or myocardial infarction within 6 months prior to start of study~* Pregnant or nursing women are ineligible~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after study participation~* No documented history of human immunodeficiency virus (HIV) infection~* No history of chronic liver disease~* Ejection fraction ≥ 45%~* No significant history of non-compliance to medical regimens or inability to give reliable informed consent~PRIOR CONCURRENT THERAPY:~* Previous treatment related toxicities should be resolved to grade 1 or better~* No other investigational agents within 14 days prior to the start of study~* No chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to start of study~* No major surgery within 2 weeks prior to start of study~* At least two weeks must have elapsed since the conclusion of radiation therapy and the start of gemcitabine hydrochloride, provided the acute effects of radiation treatment have been resolved

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemcitabine + Mitoxantrone (Type: EXPERIMENTAL): Gemcitabine Hydrochloride as administered as a continuous intravenous infusion (I.V.) at 10mg/m\^2/minute for 12 hours, starting on Day 1. Mitoxantrone Hydrochloride was given at a dose of 12mg/m\^2/day I.V. on days 1, 2, and 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: High Cut-Off Continuous Veno-venous Hemodialysis (CVVHD) in Patients Treated for Acute Renal Failure After Systemic Inflammatory Response Syndrome (SIRS)/Septic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Fulfilling at least two of the SIRS criteria as defined by the American College of Chest Physicians (ACCP)/Society of Critical Care Medicine (SCCM) Consensus Conference~2. Having signs of renal dysfunction~3. Requirement for catecholamine administration (norepinephrine or others)~4. Acute Physiology And Chronic Health Evaluation (APACHE II) score at enrolment greater than or equal to 19 and less than or equal to 30~Exclusion Criteria:~1. Lack of written informed consent from patients or a legally authorized surrogate~2. Duration of septic shock greater than 4 days~3. Hypoproteinemia (characterized by serum albumin less than 18 g/l)~4. End stage renal failure~5. Known active malignancy~6. Known human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infection~7. Age younger than 18 years or older than 80 years~8. Known pregnancy~9. Immunosuppression after transplantation~10. Participation in another clinical study~11. Renal replacement therapy greater than 24 hours before randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- HCO (Type: EXPERIMENTAL): High cut-off filters HCO1100
- control (Type: ACTIVE_COMPARATOR): conventional high-flux filters

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: MAGNET CRT Feasibility - Efficiency of LV Lead Placement Comparing Conventional vs. Magnetic Guidance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria/Exclusion Criteria:~1. The patient is 18 years of age or older.~2. The patient is clinically indicated for left ventricular lead placement as part of a pacing or defibrillator system.~3. The patient may be safely exposed to magnetic fields that exist in Niobe® MNS laboratory.~4. The patient is not participating in any clinical trial or studies that would conflict with the guidewire navigation/LV lead implant protocol for this study.~5. The patient is not pregnant, and if of childbearing potential has completed a pregnancy test which resulted negative.~6. The patient does not have an implanted pacemaker or defibrillator, unless such device will be explanted or otherwise deactivated during this procedure.~7. The patient has no contraindications for contrast dye injection.~8. The patient's diastolic blood pressure is greater than 40 mm Hg.~9. In the opinion of the investigator, the patient's general health status does not preclude participation in the study.~10. In the opinion of the investigator, the patient is a reasonable candidate for participation in this study.~11. The patient is not expected to undergo a heart transplant in the next 6 months.~12. The patient does not have a mechanical triscupid heart valve.~13. The patient has not had a myocardial infarction, unstable angina, percutaneous coronary intervention, or coronary artery bypass graft during the preceding 30 days prior to enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Effect of rTMS in Vasculitic Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of vasculitic neuropathy~* Neuropathic pain of constant severity since not less than a month and requiring use of analgesics more than once a week~* Score of 30 milimeter or more on the 100 milimeter visual analog scale of pain intensity at inclusion~Exclusion Criteria:~* Severe depression~* Personality disorders and other psychiatric conditions, which could disturb the participation in the study~* Cognitive deficits, which could disturb the participation in the study~* Contraindications for rTMS as listed by the Guidelines of the International Federation of Clinical Neurophysiology (Rossi et al. 2009) i.e. seizure in the past, epilepsy, presence of magnetic material in the reach of magnetic field, pregnancy, likelihood to get pregnant, intracranial electrodes, cardiac pacemaker or intracardiac lines, frequent syncopes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active repetitive transcranial magnetic stimulation (Type: EXPERIMENTAL): 10 hertz (Hz) rTMS will be administered over the primary motor area. Therapy will include 5 daily sessions (on consecutive week days). In every sessions 1500 magnetic pulses of 90% of the resting motor threshold intensity will be elicited.
- Sham repetitive transcranial magnetic stimulation (Type: SHAM_COMPARATOR): Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: High Schools- High on Life: an Intervention to Reduce Excessive Drinking in Danish High Schools

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Enrolled in High school that participate in The Danish National Youth Study 2019~* General High Schools~Exclusion Criteria:~* non General High schools students~* non participation in The Danish National Youth Study 2019

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: EXPERIMENTAL): The intervention consist of three main components.~School environmental component~The component targeting the high school environment consisted of two separate elements:~* Revision of school alcohol policy~* Appointment of coordinator(s) of student committees organizing events, where alcohol is sold, and student introduction committee.~Student components~The Student components consisted of three main elements:~* Web-based education for the student committees organizing events where alcohol is sold and the student introduction committee~* Pocket movie campaign~* Social norms campaign~Parent components~The parent component consisted of three separate elements:~* Parent Information Meeting~* Parent Information Folder~* Parent Information Website
- control group (Type: NO_INTERVENTION): Control high schools was asked to continue business as usual and promised to receive the intervention in the school year starting in 2020

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provide informed consent~* Age ≥ 18 years and of either sex~* Willing to comply with protocol instructions, including allowing all study assessments~* Have a venous leg ulcer (VLU) between the knee and ankle (at or above the malleolus), with a surface area ≥ 4.0 cm x cm and ≤ 15.0 cm x cm~* Venous insufficiency confirmed by duplex Doppler ultrasound examination for valvular or venous incompetence~* Arterial supply adequacy confirmed~* Target ulcer involves a full thickness skin loss, but WITHOUT exposure of tendon, muscle, or bone~* Target ulcer duration ≥ 12 weeks but ≤ 104 weeks (24 months).~* Acceptable state of health and nutrition~Exclusion Criteria:~* History of anaphylaxis, serum sickness, or erythema multiforme reaction to aprotinin, bovine serum albumin or bovine serum proteins, penicillin, streptomycin, amphotericin B or any other component of HP802-247,or known sensitivity to Iodine~* Prior diagnosis of Systemic Lupus Erythematosus with elevated anti-DNA antibody titers, Buerger's disease (thromboangiitis obliterans), current diagnosis of vasculitis, or current diagnosis of claudication~* Therapy with another investigational agent within thirty (30) days of Screening, or during the study, or any participation in a previous HP802-247 trial~* A target ulcer of non-venous etiologies (e.g., sickle cell anemia, necrobiosis lipoidica diabeticorum, pyoderma gangrenosum, vasculopathic or vasculitic)~* Documented history of osteomyelitis at the target wound location within 6 months preceding the Screening Visit~* Refusal of or inability to tolerate compression therapy~* Therapy of the target ulcer with Collagenase Santyl® ointment, autologous skin graft, biological dressings or living cell products (e.g., Oasis®, Apligraf™, Dermagraft™) within 30 days preceding the Screening Visit~* Therapy of the target ulcer with topical growth factors within 1 week preceding the Screening Visit~* Current therapy with systemic antibiotics~* Current systemic therapy with cytotoxic drugs~* Current therapy with chronic (\> 10 days) oral corticosteroids~* Current therapy with TNFα inhibitors~* History of cancer in the preceding 5 years (other than carcinoma in situ of the cervix or adequately treated non-melanoma skin cancers)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HP802-247 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: COLchicine to Prevent Sympathetic Denervation After an Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age from 18 to 80 year old~* Hospitalization within 12 hours of onset of acute chest pain~* Patient must have suffered a documented acute myocardial infarction~* Coronary occlusion on initial angiography (culprit artery with aTIMI (Thrombolysis in Myocardial Infarction) flow 1 or 0)~* Patient eligible for a revascularization procedure by PTCA (Percutaneous transluminal coronary angioplasty)~Exclusion Criteria:~* Patients with a history of myocardial infarction prior to the current episode~* Patient in cardiogenic shock or with hemodynamic instability~* Patients with severe hepatic or renal dysfunction (GFR ≤30 mL/min)~* Pregnant women or women of childbearing age without contraception~* Treatment with a potent CYP3A4 inhibitor or a P-glycoprotein inhibitor in patients with renal or hepatic impairement~* Association with macrolides (except spiramycin)~* Association with pristinamycin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Colchicine (Type: EXPERIMENTAL): colchicine and standard therapy
- Comparator (Type: NO_INTERVENTION): standard therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fibrinogen as a Surrogate for Global Haemostasis in Plasma Exchange

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* plasma exchange therapy due to humoral rejection after kidney transplantation~Exclusion Criteria:~* hereditary coagulopathy~* chronic liver disease (Child C)~* therapeutic anticoagulation~* malnutrition (BMI\<17.5)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Humoral rejection, TPE (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Fasting on Success Rates of Assisted Reproductive Techologies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women aged 25 to 38 years with planned IVF / ICSI~* 1 ng/ml ≤ Anti-Mullerian Hormone (AMH) ≤ 4 ng/ml~* Unfulfilled desire to have children \>1 year~* 25 kg/m² ≤ BMI ≤ 35 kg/m² declaration of consent~Exclusion Criteria:~* Language barriers~* Previously known serious mental illness or cognitive impairment~* Patients with anatomical/organic damage and proven uterine abnormalities~* Eating disorders in the medical history~* Serious previous internal diseases~* Lack of internet access~* No consent to randomisation~* Participation in other studies

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 38 Years
- Healthy Volunteers: f

Study Arms:
- Fasting group (Type: EXPERIMENTAL): Participants will be councelled and accompanied to follow a fasting regime of 7 days in an outpatient setting under medical supervision.
- Waiting list (Type: NO_INTERVENTION): This group maintains their individual diet during the whole time of the study. In case that the first cycle of In-Vitro-Fertilization fails, they are offered a fasting intervention before a next cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues